Treatment of ocular diseases and disorders using lantibiotic compositions

• US 20050250681A1
• Filed: 05/06/2005
• Published: 11/10/2005
• Est. Priority Date: 05/06/2004
• Status: Active Grant

• Current Assignee: Molichem Medicines Incorporated
• Original Assignee: Molichem Medicines Incorporated
• Inventors: Molina, Luis
• Granted Patent: US 7,479,481 B2
• Time in Patent Office: Days
• US Class Current: 514/2.900
• CPC Class Codes: A61K 38/12 Cyclic peptides , e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C A61K38/043 - A61K38/046 take precedence
• CPC Class Codes: C12N 2533/54 Collagen; Gelatin
• CPC Class Codes: C12N 5/0629 Keratinocytes; Whole skin

Abstract

Compositions and methods for treating ocular diseases and disorders are provided. The composition can contain at least one lantibiotic, which can be administered topically by injection, systemically, or by other appropriate means. The methods provided include the administration of a therapeutically effective amount of a formulation containing at least one lantibiotic to the appropriate section of the eye.

Claims

1. A method for treating an ocular disease or disorder in a mammal comprising administering an effective amount of a lantibiotic to the mammal, wherein the ocular disease or disorder is selected from the group consisting of allergies, glaucoma, cataract, corneal disease, vitreo-retinal diseases, diseases and disorders of the optic nerve, oculosystemic diseases and disorders, diseases and disorders of the uvea and/or a diabetic eye disease.

2. The method of claim 1, wherein the lantibiotic is the compound of Formula I:

3. The method of claim 1, wherein the lantibiotic is a Type A or Type B lantibiotic.

4. The method of claim 3, wherein the lantibiotic is a Type B lantibiotic.

5. The method of claim 4, wherein the Type B lantibiotic is duramycin.

6. The method of claim 1, wherein the lantibiotic is administered in combination or alternation with an aminoglycoside.

7. The method of claim 6, wherein the aminoglycoside is tobramycin.

8. The method of claim 1, wherein the corneal disease is selected from the group consisting of corneal abrasion, conjunctivitis, corneal infections, Fuchs'"'"' Dystrophy, Herpes Zoster (shingles), Iridocorneal Endothelial Syndrome, keratoconus, Lattice Dystrophy, Map-Dot-Fingerprint Dystrophy, ocular Herpes, pterygium and Stevens-Johnson Syndrome.

9. The method of claim 1, wherein the diabetic eye disease is a diabetic retinopathy, cataract or glaucoma.

10. The method of claim 1, wherein the vitreo-retinal disease is selected from the group consisting of diabetic retinopathy, macular degeneration, retinal detachment, macular holes, retinopathy of prematurity, retinoblastoma, uveitis, eye cancer, flashes, floaters and retinitis pigmentosa.